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A B S T R A C T
Ethnopharmacological relevance: In spite of the rich bio-cultural diversity found in the Neotropics relatively few
herbal drugs native to South America are included in the global pharmacopoeia.
Material and methods: In the attempt to historically explain the inclusion of herbal drugs into official pharma-
copoeias we consider the disparate epidemiology and cultural evolution of the New and the Old World. We then
trace the development of pharmacopoeias and review forces that worked towards and against the synchroni-
zation of pharmacopoeias and highlight the role of early chemical and pharmacological studies in Europe.
Finally, we compare the share of exotic and native herbal drug species included in the Brazilian Pharmacopoeia
with the share of exotic and native species included in the European Pharmacopoeia as well as those used for
products registered with ANVISA.
Results: The domination of Eurasian herbal drugs in the European Pharmacopoeia seems to be conditioned by
the geographical extension of Eurasia, which facilitated the interchange of materia medica and the creation of a
consensus of use since ancient times. At the time of the Conquest the epidemiology of the Amerindian popu-
lations resembled that of pre-agriculturalist societies while no written consensus around efficacious medicine
existed. Subsequently, introduced and well-tried plant species of the Old World gained therapeutic importance in
the New World.
Conclusion: The research focus in Europe and the US resulted in a persistence of herbal drugs with a historic
importance in the European and US pharmacopoeias, which gained a status as safe and efficacious. During the
last decades only few ethnopharmacological field-studies have been conducted with indigenous Amerindian
groups living in the Brazilian Amazon, which might be attributable to difficulties in obtaining research per-
missions. Newly adopted regulations regarding access to biodiversity and traditional knowledge as well as the
simplified procedure for licencing herbal medicinal products in Brazil prospects an interesting future for those
aiming at developing herbal medicine based on bio-cultural diversity and respecting the protocols regulating
benefit sharing.
1. Introduction
1.1. Biodiversity and cultural diversity of Brazil
The American continent harbours around 125,000 native vascular
plant species (Ulloa et al., 2017; Tropicos: http://www.tropicos.org/
Project/VPA) or 33% of the known 383,000 vascular plants species
worldwide (Ulloa et al., 2017). Particularly rich are the Neotropics with
an estimated 90,000 to 110,000 plant species (Antonelli and Sanmartín,
2011), half of which occur in the Amazon basin (Hubbell et al., 2008).
With up to 50,000 species, Brazil has the largest flora in the Neotropics
(Lewinsohn and Prado, 2005; Shepherd, 2003; Ulloa et al., 2017). Be-
sides a rich biodiversity around 300 Amerindian groups (including ca.
900,000 individuals) associated with 274 different languages are living
in Brazil (IBGE, 2019; survivalinternational.org). Around 325,000 live
now in urban and 570,000 in rural areas (ISA, 2019; IBGE, 2019).
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Moreover, around 2700 culturally distinct Quilombola communities,
formed by descendants of Afro-Brazilian runaway slaves, exist
throughout the country (FCP, 2019). Several communities living mostly
in rural areas are derived from the miscegenation of European, Amer-
indian, and Afro-Brazilian descendants including Caboclo river
dwellers, coastal Caiçara fishermen, Seringueiro rubber tappers and
Jangadeiro raftsmen (Ribeiro, 2018).
1.2. Herbal drugs from the neotropics included in the European
Pharmacopoeia
Although the different indigenous groups of Brazil and the Americas
in general have a long standing tradition regarding the practice and
understanding of herbal medicine and materia medica (e.g., Rodrigues,
2006; Odonne et al., 2013; Monigatti et al., 2013; van Andel et al.,
2014; Bieski et al., 2015; Paniagua-Zambrana et al., 2015; Geck et al.,
2016; Pedrollo et al., 2016, Ribeiro et al., 2017) relatively few medic-
inal plants native to the Americas and specifically Brazil have been
developed into globally important herbal medicines (Brandão et al.,
2008; Heinrich et al., 2014; Dutra et al., 2016). Currently, the European
Pharmacopoeia (Ph. Eur. 9.5, 2017) includes 30 monographs treating
18 herbal drug aggregates native to Meso and South America1 (see
Fig. 1, Table 1 and Supplementary Table A).
Several herbal drugs from the Neotropics were of historical im-
portance in Europe and the USA but later excluded from pharmaco-
poeias and dispensatories. For example, the core wood of Guaiacum
officinale L. (lignum vitae) was imported to Europe from the West Indies
(Caribbean archipelago) as a cure for syphilis, but later found to be
ineffective and thus abandoned (Waugh, 1982; Mann, 1984). Other
sudorific drugs such as the root of Sarsaparilla (Smilax spp.) from Me-
soamerica (Felter and Lloyd, 1898) and lignum sassafras (Sassafras al-
bidum (Nutt.) Nees) from North America were used as substituents for
the ineffective G. officinale until it was realized that also these drugs
were not effective (Munger, 1949). Jalap root (also named ‘root of
Michoacán’, mostly Ipomoea purga (Wender) Hayne but also including
roots of other Ipomoea spp., see Pereda-Miranda et al. (2006) and
Linares and Bye (1987)) is described in the ‘Codex de la Cruz Badiano’
(Gates, 2000) as well as in the ‘Historia Natural de Nueva España’
(Hernández, 1959: II, 456). This was imported to Europe as a substitute
for Mediterranean purgatives such as scammony (Convolvulus scam-
monia L.) as early as 1610 (Castañeda-Gómez and Pereda-Miranda,
2011). Jalap root was included in the commentary to the American
pharmacopoeia, the Dispensatory of the United States (Wood and
Bache, 1833) and still appeared in the 25th edition of the Dispensatory
of the United States of America (Osol and Farrar, 1955) but later ex-
cluded. Also in Europe, jalap root was included in several important
pharmacy books (e.g. Stocker, 1810; Bigelow, 1822; Felter and Lloyd,
1898) and was part of the Edinburgh New Dispensatory (Duncan, 1803)
as well as the London Dispensatory (Thomson, 1826). Jalap was also
present in the German Pharmacopoeia from 1872 and 1926 among
descriptions for preparations of drugs such as Tinctura Resinae Jalape,
Tubera Jalapae, Resina Jalapae, Pilulae Jalapae and Sapo jalapinus, but
excluded in the following versions (Eich, 2008). The reason for ex-
cluding jalap root from the officinal materia medica was that even
minimal overdosing may cause sever inflammations of the mucous
membranes of the intestine and colon due to the resin glycosides, which
are able to dissolve lecithin from the epithelial intestinal cells (Eich,
2008). Another remarkable example is Quassia amara L., popularly
known as ‘Quinquina de Cayenne’, which was widely used as a febri-
fuge and antimalarial drug in Europe, and included in some European
pharmacopoeias such as the Pharmacopoeia of the Royal College of
Physicians of London (Healde and Latham, 1793) and the Farmacopea
Oficial Española, (6th edition from 1884) as well as in several im-
portant medical books (e.g., Gray, 1821; Christison, 1842; Felter and
Lloyd, 1898; Cullen, 1789). The extract and derivatives of Q. amara
leaves have been proven active against malaria in vivo (Ajaiyeoba et al.,
1999; Bertani et al., 2006) and the potent antimalarial and anticancer
simalikalactone E has been patented, but accusations of biopiracy are
hampering any further development into a pharmaceutical drug (see
Bourdy et al. (2017) for a thorough discussion). Q. amara wood is
mentioned in the British Herbal Pharmacopoeia from 1996, the British
Herbal Compendium from 1992, the 32nd edition of Martindale (The
Complete Drug Reference) and the second edition of the Physicians'
Desk Reference for Herbal Medicine but it is not included in the Ph. Eur.
9.5 (2017). Cascarilla stem bark, predominantly deriving from Croton
eluteria (L.) W. Wright or Croton cascarilla (L.) L. (Evans et al., 2009)
was much appreciated for its bitter and aromatic quality and used as a
tonic stimulant, for treating fever, vomiting, dysentery and menor-
rhagia (Gray, 1821). It was often combined with Cinchona sp. bark and
generally prepared as an infusion (Thomson, 1862) but currently not
included in the Ph. Eur. or the U.S. Pharmacopoeia (USP). Extracts of
coca (Erythroxylon spp.) were included in the Farmacopea Oficial
Española (Anonymous, 1884) as ‘Vino de coca del Perú’ and in Felter
and Lloyd (1898) as ‘Vinum Erythroxili’ but today coca leaves are
banned from being imported and sold in Europe and the US under the
‘Single Convention on Narcotic Drugs’ from 1961. Thus, pharmaco-
poeias and dispensatories are not static while the inclusion and per-
sistence of (herbal) drugs in pharmaceutical compendia is related to
their effectiveness and safety as well as dependent on political con-
siderations.
2. Research question
In the attempt to explain the inclusion and exclusion of herbal drugs
into pharmacopoeias we pursue the question as to why only few herbal
drugs native to Meso- and South America, and specifically Brazil, are
included in the Ph. Eur. 9.5 (2017) as well as in the current edition of
the Brazilian Pharmacopoeia (2010), notwithstanding the rich bio-
cultural diversity of the Neotropics.
3. Methodology
3.1. Organization of the text
The article assumes a historical perspective using the different
epidemiology and cultural evolution of the New (Americas) and the Old
World (Eurasia and Africa) as a backdrop against which the develop-
ment of herbal medicine and pharmacopoeias is projected. In section 4
we consider the epidemiological situation of pre-Columbian America
and the relatively short interaction with Old World crowd diseases in
the differential development of herbal medicine with respect to the Old
World. With the help of existing literature we discuss the origin and
purpose of pharmacopoeias and sketch the development of pharmaco-
poeias in Europe and the Western world (section 5) pointing out how
newly discovered and occupied territories during the period of coloni-
zation and the search for efficacious medicines led to the inclusion of
exotic herbal drugs and remedies. In sequence, the racial, economic and
social forces working towards and against the process of homogeniza-
tion of herbal pharmacopoeias are reviewed. In section 6 always based
on the analysis of existing literature, we explain how early efforts in
1 1. Arachis hypogaea L., 2. Myroxylon balsamum (L.) Harms var. perierae
(Royle) Harms, 3. Myroxylon balsamum (L.) Harms var. balsamum, 4. Peumus
boldus Molina, 5. Capsicum annuum L. and Capsicum frutescens L., 6. Cinchona
pubescens Vahl (Cinchona succirubra Pav.), Cinchona calisaya Wedd., (Cinchona
ledgeriana Moens ex Trimen), 7. Gossypium hirsutum L. and Gossypium spp., 8.
Paullinia cupana Kunth, 9. Helianthus annuus L., 10. Carapichea ipecacuanha
(Brot.) L. Andersson (Cephaelis ipecacuanha (Brot.) A. Rich., Cephaelis acuminata
H.Karst.), 11. Ilex paraguariensis A.St.-Hil., 12. Passiflora edulis Sims, 13. Quillaja
saponaria Molina, 14. Krameria lappacea (Dombey) Burdet & B.B. Simpson, 15.
Datura stramonium L., 16. Aloysia citrodora Paláu, and the pantropical: 17. Cocos
nucifera L. and 18. Eclipta prostrata (L.) L.
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pharmacognosy and chemistry in Europe led to a preferential in-
vestigation and characterization of herbal medicines and chemicals
included in the official European pharmacopoeias and generally of
those herbal drugs widely used in Europe and thus commercially im-
portant, whether exotic or native.
In section 7 we finally sketch the development of the Brazilian
Pharmacopoeia and compare the herbal drugs included in the latest
version with those herbal drugs licenced by the ‘Agência Nacional de
Vigilância Sanitária do Brasil’ (ANVISA database 2016, see Carvalho
et al., 2018) and those included in a popular book entitled ‘Plantas
Medicinais no Brasil: Nativas e Exóticas’ (Lorenzi and Matos, 2008). We
showcase how exotic species dominate the officinal and licenced pro-
ducts and highlight the untapped potential of traditional herbal medi-
cine and biodiversity of Brazil.
3.2. Selection of references for comparison
‘Plantas Medicinais no Brasil: Nativas e Exóticas’ reflects a con-
sensus about the most important medicinal plants used in traditional
and folk herbal medicine across Brazil (Lorenzi and Matos, 2008 p. 5)
and has not the pretention to be complete. It was chosen as a reference
for this comparison because it is one of the few and better books on this
subject for Brazil suiting the purpose. Alternatively the 6 vols. by
Manuel Pio Correia entitled ‘Dicionário das Plantas Úteis do Brasil e das
Exóticas Cultivadas’, published from 1926 onwards and containing
approximately 10,000 species could have been used. However, Pio
Correia (1926) does not follow a consensus approach of ethnobotanical
uses and the taxonomy is outdated. .
3.3. Handling of monographs, herbal drug species and their geographic
distribution
Herbal drug monographs in the European Pharmacopoeia 9.5
(2017) treating the same herbal drug species (e.g. Thymi herba and
Thymi typo thymolo aetheroleum) were aggregated and counted as one,
as well as alternative herbal drug species of the same genus included in
one monograph (e.g. Salix purpurea L., S. daphnoides Vill., S. fragilis L.)
and termed “herbal drug aggregates”. The two monographs on Bal-
samum peruvianum (Myroxylon balsamum (L.) Harms var. perierae
(Royle) Harms) and Balsamum tolutanum (Myroxylon balsamum (L.)
Fig. 1. Map showing the natural geographical distribution of the 219 herbal drug aggregates included in Ph. Eur. 9.5 (2017). The numbers before a ‘+’ indicate the
number of herbal aggregates deriving from that geographical unit while the numbers after a ‘+’ indicate the number of herbal drug aggregates with a larger
distribution area and occurring in the adjacent areas as well. The pie chart reading starts at 12:00 (Africa 4%). Supplementary Table A reports the native distribution
for each herbal drug aggregate.
Table 1
The 219 herbal drug aggregates included in the Ph. Eur. 9.5 (2017) arranged by
their native distribution.
Origin n Origin n
A Africa 9 N Eurasia + Greenland 1
B America (M) 2 O Europe 14
C America (M,N) 2 P Europe + Africa (N) 9
D America (M,S) 3 Q Europe + Africa (N) + Asia (CW) 2
E America (N) 11 R Europe + Africa (N) + Asia (SW) 14
F America (S) 9 S Europe + Africa (N) + Asia (W) 3
G Asia 70 T Europe + America (N) 1
H Asia (SE) 6 U Europe + Asia (SW) 2
I Asia (SW) 2 V Europe + Asia (W) 2
J Asia (W) 3 W Northern Hemisphere 14
K Australia 2 X Temperate regions 2
L Eurasia 19 Y Tropics 2
M Eurasia + Africa (N) 14 Z Undefined 1
TOTAL 219
CW: Central and West; M: Meso; N: North; S: South; SE: Southeast; SW:
Southwest; W: Western.
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Harms var. balsamum) were treated separately. Homeopathics and
starch sources were not considered but Cetraria islandica (L.) Ach. was
included. For the 5th Brazilian Pharmacopoeia (ANVISA, 2010) we
considered the 56 herbal drug monographs as 55 herbal drug ag-
gregates including 54 plant species and two subspecies of Myroxylum
balsamum (without considering taxa used for the production of sugar
and starch).
Latin names appearing in the Ph. Eur. 9.5 (2017) as well as the
Brazilian Pharmacopoeia (ANVISA, 2010) have been adapted according
to www.theplantlist.org while for the geographical distribution of the
herbal taxa the broad natural distribution patterns according to several
modern floras, such as the Flora of North America (http://www.efloras.
org/flora_page.aspx?flora_id=1), the Flora of China (http://www.
efloras.org/flora_page.aspx?flora_id=2), the Flora do Brasil 2020
(http://floradobrasil.jbrj.gov.br/) and the Flora Iberica (Castroviejo
et al., 1986–2012) were followed. As the geographical origin, especially
that of cultivated taxa, is often not exactly known, we define ‘native
distribution’ as the geographical distribution for which human activity
is apparently not responsible. For cultivated plants we have followed
the native distributions mentioned in Zohary and Hopf (2000).
4. Epidemiology in the Old World and the New World and
consensus about herbal medicines
Agriculture and animal husbandry evolved independently in various
regions of the world but started first in the fertile-crescent in
Mesopotamia (Zohary and Hopf, 2000; Diamond, 2002). The Neolithic
Demographic Transition together with animal husbandry in the Old
World increased the probability of zoonotic pathogen transfer resulting
in many human infectious crowd diseases such as measles, influenza,
pertussis, diphtheria and smallpox (Diamond, 2002; Comas et al.,
2013). These viral and bacterial infections spread to humans from
epidemic diseases endemic to domestic (herd) animals, and depend on
dense host populations in order to sustain themselves (Diamond, 2002).
Also the altering dietary patterns and working habits emerging during
the Neolithic revolution contributed to the changing epidemiology in
the Old World. The greater health risk farmers were exposed to,
therefore increased the interest in plants with medical values while,
additionally, wild famine foods were important when the crop harvest
failed. Brown (1985) pointed out that traditional agriculturalists dis-
tinguish generally more wild plant species than hunter-gatherers.
Agriculturalists began to find their medicines among cultivated crops
and wild food plants as well as the weedy flora adapted to the ecolo-
gical niches created by their own activity (Logan and Dixon, 1994;
Leonti et al., 2006). Out of the 25 major infectious diseases responsible
for the highest mortality and morbidity in human history an un-
ambiguous New World origin could only be established for Chagas’
disease (Wolfe et al., 2007). For syphilis the situation remains unclear
and the debate about its origin is ongoing (Wolfe et al., 2007) but
historical data point towards a New World origin (Waugh, 1982; Mann,
1984, p. 215). There is supporting evidence that human tuberculosis
originated in Africa over 70,000 years ago (Comas et al., 2013) yet the
current Mycobacterium tuberculosis strains of the Americas are closely
related to European strains (Bos et al., 2014). The analysis of M. tu-
berculosis genome found in pre-Columbian mummies suggests a zoo-
notic transfer from pinnipeds around 700 to 1000 CE, which pre-
sumably contracted M. tuberculosis from an African host and transferred
the germs to South America (Bos et al., 2014). This would be compa-
tible with the occurrence of pre-Columbian skeletal lesions attributed to
M. tuberculosis infections (Bos et al., 2014). No data supporting any
conclusion regarding their geographical origin are available for rota-
virus, rubella, tetanus and typhus while for the other 18 pathogens an
Old Word origin is almost certain (Wolfe et al., 2007). In contrast,
agriculturalists and hunter-gatherers in the New World had to deal with
fewer infectious diseases before the European Conquest, due to limited
domestication of herd animals. Epidemiological data further suggest
that Amerindian populations generally suffer a higher incidence of
gastrointestinal problems, such as bile acid metabolism disorder, gall-
stone diseases, biliary tract and gallbladder cancer (Michaud, 2002;
Shaffer, 2006). On top of that has the adoption of a westernized diet
and life-style by Amerindian populations resulted in an increase in the
prevalence of diabetes, obesity, hypertension and dyslipidemia and
augmented the probability for contracting cardiovascular complications
such as atherosclerosis and stroke (Broussard et al., 1991; Galloway,
2002). This seems to be associated with genes permitting an effective
food metabolism (the so called “thrifty” genes), which are important for
survival in nutritionally less predictable environments but become a
risk factor when food becomes affluent (Hanis et al., 1986; Diamond,
2003). As a consequence, pre-Columbian traditional medicine is and
was shaped by a different epidemiological context when compared to
Old World medicine.
Moreover, the lack of written languages [the few surviving Maya
codices are an exception] hampered the building of a large consensus
about efficacious pre-Columbian medicines and reduced the possibility
for cumulative knowledge transmission (see Lewis and Laland, 2012;
and Leonti et al., 2015 for concept and mechanisms). Today some of the
most widely used herbal remedies in rural areas and by indigenous
groups in northern South America are introduced from Eurasia, Africa,
North America and the Pacific (Bennett and Prance, 2000; see also
Lorenzi and Matos, 2008). Although Leishmaniasis is endemic and na-
tive to tropical South America, for instance, many of the most fre-
quently reported remedies from a cross-cultural analysis of 291 herbal
species (Odonne et al., 2017) are cultivated or/and exotic.
It is, however, highly likely that, due to their more isolated sub-
sistence, indigenous Amerindian groups show a much higher idiosyn-
crasy of native medicinal plant use (see e.g., Prance, 1973; Schultes and
Raffauf, 1990; Milliken and Albert, 1996; Doyle, n.d.). During the last
decades however, only few field studies have been conducted with in-
digenous Amerindian groups living in the Brazilian Amazon. This might
be attributable to logistic issues and difficulties in obtaining permission
from government agencies such as the FUNAI (Fundação Nacional do
Índio) and the MMA (Ministério do Meio Ambiente).
5. Development of pharmacopoeias with a focus on Europe
5.1. Origin and purpose of pharmacopoeias and the inclusion of exotic drugs
Pharmacopoeias have their origin in local, regional and over-re-
gional consensus collections of therapeutic knowledge about remedies
derived from plant, animal, fungal and mineral origin. Such texts were
called materia medica, then compositiones medicamentorum, antidotarii or
dispensatorii, later on ‘herbals’ and finally ‘pharmacopoeias’ (Urdang,
1951) and testify to the early inclusion of exotic herbal drugs (Heffter,
1914). The first texts reproducing knowledge on materia medica (e.g.,
Ebers papyrus (ca. 16th century BCE, Egypt), Corpus Hippocraticum
(Hippocrates and allies, 600-200 BCE, Greece), ‘Enquiry into Plants’
(Theophrastus, ca. 370-285 BCE, Greece), De Materia Medica (Dioscor-
ides, 1st century CE, Greece), ‘Shennong Bencaojing’ (The Classic of
Herbal Medicine, ca. 200–245 CE, China), the ‘Bower Manuscript’ (by
Buddhist monks, ca. 600 CE, India)) were compiled on the perceived
consensus of the therapeutic and commercial importance of the drugs
used in a certain geographical area, and intended as a reference stan-
dard for medical doctors and their aspirants as well as those selling and
compounding medicines (Urdang, 1951; Unschuld, 1986; Heinrich
et al., 2004; Leonti and Verpoorte, 2017).
Today, the armamentarium of drug treatment is transmitted
through ‘pharmacopoeias’, which are standard publications regulating
the quality of pharmaceutical drugs, excipients and flavouring correc-
tives, specifying their testing methods, purity, storage instructions,
composition and concentration. Pharmacopoeias secure the uniformity
of remedies approved by representatives of a specific political unit and
make the quality standards obligatory (Urdang, 1951, p. 583). The
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usefulness of a pharmacopoeia (literally ‘drug making’) is “determined
by the periodical changes it has to undergo to keep pace with the latest
progress in the sciences on which it is based” (Urdang, 1951, p. 577).
With respect to herbals, pharmacopoeias are distinguished in that they
are legally binding quality standards and do not include therapeutic
recommendations. This legally binding character has an imminent im-
pact on the continuity of drug use. The pharmacopoeia of the city of
Florence (Florentine ‘Nuovo Receptario’) from 1498 is regarded as the
first official pharmacopoeia (Urdang, 1951; Corradi, 1966). Among the
first true official state pharmacopoeias are the ‘Ricettario Fiorentino’
from 1573 (Grand Duchy of Tuscany) and the Pharmacopoeia Londi-
nensis from 1618 (Realme of England) (Urdang, 1951).
In any event, the development of official pharmacopoeias was
strongly influenced by the separation of medicine from pharmacy, a
functioning public welfare system and the idea that the state is re-
sponsible for the health of its citizens (Urdang, 1951). A crucial step for
the development of the European pharmacopoeias was the integration
of indigenous drugs “discovered” during the colonial expansions of
European kingdoms (e.g., Heffter, 1914, p. 16). The prospect of finding
new medicines, new therapeutic solutions as well as spices was, in fact,
an incentive for many conquerors and adventurers and resulted in a
diversification of European materia medica and textbooks about exotic
and indigenous drugs written by explorers, friars and commentators
such as Garcia da Orta (1501–1568, ‘Coloquios dos simples e drogas he
cousas mediçinais da India’ (India); da Orta, 1983), Nicolás Monardes
(1574, ‘Historia medicinal de las cosas que se traen de nuestras Indias
Occidentales’ (New World)), Francisco Hernández (1514–1587 ‘His-
toria Natural de Nueva España’, (Mexico); Hernández, 1959–1967), de
Saint Hilaire (1772–1844 ‘Plantes usuelles des Brésiliens’, (Brazil); de
Saint Hilaire, 2014), De Martius (1843, Systema materiae medicae ve-
getabilis Brasiliensis (Brazil)) and others (see Mann, 1984; Giorgetti
et al., 2007; Brandão et al., 2012; Breitbach et al., 2013; Heinrich et al.,
2014; Helmstädter, 2017; Leonti and Verpoorte, 2017; Rivera et al.,
2017; Ricardo et al., 2018). This development culminated in the
(transient) wealth of many European city-states depending on the
herbal drug and spice trade (Tschirch, 1910). Moreover, from the 16th
century onwards, herbal drugs have been cultivated wherever geo-
graphical, climatic and ecologic conditions allowed for economic pro-
duction (Tschirch, 1910). Frequently the cultivations far from their
native habitats were more productive as the pests and diseases were left
behind (Prance, 2005 p. 28).
The many new herbal drugs and exotic plant species that arrived
from overseas led to a rekindled interest in systematic botany and the
attempt to systematize and assess the various herbal drugs used in folk-
medicine in Europe and introduce them in medicine (Heffter, 1914 p.
16–17).
5.2. Racial, nationalistic and economic considerations affecting the
homogenization of pharmacopoeias
Notwithstanding the increasing globalization and the synchroniza-
tion of pharmacopoeias, which finally led to the European as well as the
International Pharmacopoeia, the process was characterized by racial
and political considerations as well as erroneous beliefs. According to
Urdang (1951) “in earlier days … it was thought that drugs originating
in a certain country had an especially beneficial relation to the bodies of
the residents of their common habitat” (Urdang, 1951, p. 583), which is
also reflected in the introduction of the Pharmacopoeia Londinensis from
1618, which reads: “Why should not the citizens of London have their
own? [Pharmacopoeia] … the appreciation of which does not arise so
much from its being precious, but from its being appropriate and well-
adapted to English bodies” (Urdang, 1951, p. 584). According to Heffter
(1914, p. 17) already at the beginning of the 16th century in Germany
and France the idea circulated that those plants, which grew under-
neath the hot sun would not be salubrious to inhabitants of the tem-
perate zone while Paracelsus (1493–1541) as well as
Tabernaemontanus (1522–1590) thought that plants growing in a type
of land and air are most beneficial to those, who were born and live
there (Heffter, 1914, p. 17).
Similar ideas can still be found in recent articles, for example that by
Pandalis and Keil (2014, p. 75), stating that “the concept explains why
medications, which are proven for centuries are essential for health –
but exclusively within their respective ethno-context”. This not only
reminds us of gene polymorphism responsible for drug metabolism, but
also of the concept of ‘local biologies’, referring to the fact that human
biology shows universal and local characteristics (Niewöhner and Lock,
2018). A similar idea was the belief that the geographic origin of a
disease would coincide with the origin of effective drugs (Mann, 1984).
This makes sense in the light of a long bio-cultural interaction, i.e. a
local trial and error approach to find appropriate drugs. Another factor
that prevented the homogenization of pharmacopoeias were nationa-
listic ideologies and economic considerations leading to preferential
inclusion of locally sourced and produced drugs on the expense of
exotic drugs (Urdang, 1951). Urdang's (1951, p. 596) idealistic view of
pharmacy is that in a similar fashion to medicine it is “an organized
human attempt to meet elementary human needs not restricted to na-
tionality, creed, or environment” and therefore “by its very nature in-
ternational”. Similarly, Tschirch (2015, p. 22) noted in 1909, that “we
don't ask anymore where a remedy is coming from but if it's effective”.
Giving way to the pressure of global trade, can however, have an
immediate impact on the inclusion of materia medica as the document
A4-0075/97 by the European Parliament testifies: “The European
Pharmacopoeia, as drawn up by the Council of Europe, needs to be
opened up to other pharmacopoeiae particularly the medicinal plants
used in Chinese medicine” (Bauer and Franz, 2010). Herbal drugs from
other regions of the world, such as Ayurvedic or South American
medicines, were not considered in this working programme (Bauer and
Franz, 2010).
5.3. Inclusion of exotic herbal drug monographs in Ph. Eur. 9.5
Currently 219 herbal drug aggregates are listed in the Ph. Eur. 9.5
(2017), of which 97 (44%) are native to Europe (and adjacent terri-
tories; sum of rows L-X in Table 1) and only 12 are from South America,
four from Mesoamerica while two have a pantropic distribution (Fig. 1).
As much as 81% (178; sum of rows G-J + sum of rows L-X in Table 1) of
the herbal drug aggregates included in the Ph. Eur. 9.5 (2017) are
native to Eurasia. The many Chinese herbal drug aggregates (ca. 30, of
which currently 17 without an entry in the European Medicines
Agency), which were continuously included beginning with Ph. Eur. 6
(Bauer and Franz, 2010) certainly contribute to this high share (see
supplementary Table A). There is, however, also evidence pointing to-
wards a more historical and geographical component regarding the
inclusion of herbal drugs native to Eurasia: The vastness and the geo-
graphical extension (East-West axis) of Eurasia, with its almost identical
day-lengths, seasons, climates, habitats and diseases, facilitated the
successful exchange of a high diversity of useful germplasm, including
that of herbal medicines, spices and food plants (e.g. Allium sativum,
Brassica napus, Trigonella foenum-graecum, Coriandrum sativum, Triticum
aestivum, Sesamum indicum, Carthamus tinctorius, Linum usitatissimum;
see supplementary Table A). The North-South axis of the Americas in
contrast worked as a factor complicating the exchange of valuable
herbal species (see Diamond, 2002 for a more general discussion on this
issue). This is also supported by the so-called Rapoport's rule asserting
that while higher latitude species show larger geographical-range size,
lower latitudes support more species (Stevens, 1989; and see Leonti
et al., 2013 p. 102–103 for discussion related to plants used as medi-
cine). The favourable conditions for exchanging germplasm of proven
herbal drugs and spices as well as for commercializing herbal drugs
across Eurasian cultures since ancient times facilitated therapeutic ex-
perimentations, the diversification of uses and the inclusion of ‘exotic’
drugs into local medicinal floras and pharmacopoeias. This historical
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legacy, deriving from the consensus around local medicinal systems
across Eurasia and Northern Africa is also reflected in the Ph. Eur. 9.5
(2017).
6. The contribution of pharmacognosy to the development of
pharmacopoeias
In a collaborative effort, during the 19th century, French and
German chemists, physiologists and naturalists such as Alexander von
Humboldt (1769–1859), Friedrich Sertürner (1783–1841), Joseph
Pelletier (1788–1842), Claude Bernard (1813–1888), and others, con-
ducted ethnopharmacological field studies, isolated pure active com-
pounds and described their pharmacological effects (Bruneton, 1995,
pp. 625–642; Heinrich et al., 2004; Gertsch, 2009). The coordinated
interdisciplinary scientific investigations provided the necessary phar-
macological and toxicological basis for the inclusion of pure chemical
entities into the official pharmacopoeias (Heinrich et al., 2004; Wagner
et al., 2007; Gertsch, 2009, and see also the different official pharma-
copoeias). This development changed the character and composition of
the pharmacopoeias. While, for example, the first German pharmaco-
poeia from 1872 contained 255 herbal drugs, the 5th edition from 1910
included only 167. In parallel the presence of chemical preparations
increased from 53 in 1872 to 98 in 1910 (Heffter, 1914, p. 33). During
the 19th and early 20th century pharmacognosy flourished in Germany
(Heinrich and Anagnostou, 2017) resulting in innovative literature
mostly published in German, which contextualized history of ethno-
medicine with the latest discoveries in chemistry and pharmacology
(e.g., Köhler, 1887; Lewin, 1894; Hartwich, 1897; Tschirch,
1909–1925). Similarly, the advancement of organic and natural pro-
duct chemistry was mainly published in German during the 19th cen-
tury (e.g., Liebig, 1837; Liebig und Geiger, 1843; von Hofmann, 1843;
Kolbe, 1874; Baeyer, 1878). The chemical, pharmacological and tox-
icological characterization of the herbal drugs included in the European
pharmacopoeias as well as the main medicinal plants used in Europe
was still a major task of European pharmacognosists during the 1970s
to the 1990s. As language is the main key in knowledge transmission,
the instant access to the progresses in chemistry resulted in a strategic
advantage of German-speaking scientists. Together with the establish-
ment of scientific schools focusing on pharmacognosy and chemistry,
and according to the principles of cultural evolution and knowledge
transmission (see e.g. Cavalli-Sforza and Feldman, 1981; Diamond,
2005; Richerson and Christiansen, 2013), this allowed for a head start
in central Europe and is part of the reason why the pharmaceutical
(including those producing plant based medicines and nutraceuticals)
and chemical industry is so well established in this European region still
today (e.g. Novartis, Hoffman-La-Roche, Merck Serono, Clariant, Ciba,
Lonza, DSM, Henkel, Hoechst, BASF, Bayer, Schwabe, Weleda).
7. Development of the Brazilian Pharmacopoeia, herbal products
registered with ANVISA and plants used in popular and traditional
medicine
7.1. Development of the Brazilian Pharmacopoeia
The Historia Naturalis Brasiliae written by the Dutch physician
Willem Piso (1610–1678) and the German naturalist Georg Marcgraf
(1610–1644) is the first scientific work about the natural world and
traditional medical knowledge from Brazil (Françozo, 2010). The first
pharmaceutical codex applied in colonial Brazil was, however, the
‘General Pharmacopoeia for the Kingdom and Domains of Portugal’
(‘Farmacopeia Geral para o Reino e os Domínios de Portugal’) by A.
Tavares from 1794, and obligatory in Brazil from 1809 onwards. After
gaining independence (1822), in addition, the French ‘Codex Medica-
mentarius’ (compulsory from 1851 onwards) was used by pharmacists.
In 1882 it was established that the French Pharmacopoeia should be
followed for the preparation of remedies, until the publication of the
first Brazilian Pharmacopoeia, which saw light in 1929 (Pianetti, 2016).
There exist five editions of the Brazilian Official Pharmacopoeia
(FBRAS). The first was sanctioned in 1926 and published in 1929
(‘Brazilian Pharmacopoeia Code - Pharmacopoeia of the United States
of Brazil’) while the current edition was published in 2010 replacing the
previous 4 editions, which were all valid to this date (Pianetti, 2016).
The initial adoption of European pharmacopoeias for sure consolidated
the importance of exotic herbal drugs while the adoption of the French
Pharmacopoeia appears like an attempt to shed off the colonial identity.
7.2. Herbal drug monographs in the Brazilian Pharmacopoeia and the
presence of exotic species
In all its editions, the Brazilian Pharmacopoeia contained more
exotic than native herbal drug species (Brandão et al., 2006; ANVISA,
2010). In parallel to the replacement of ‘boticas’ (herbal dispensatories)
by pharmacies (drugstores) in succession of the isolation and synthesis
of pure pharmaceutical compounds, the number of herbal drug mono-
graphs was drastically reduced in the first three editions of the Brazilian
Pharmacopoeia (Brandão et al., 2006, Table 2). The share of native
herbal drug monographs included in the Brazilian Pharmacopoeia has
dropped from an initial 27.5% in 1929 to 15.6 and 17.4% in 1959 and
1977, respectively, but more recently (ANVISA, 2010, 5th edition) in-
creased again to 26.9% corresponding to 15 species (Table 2; Fig. 2,
supplementary table B).
The current fifth edition of the Brazilian Pharmacopoeia (ANVISA,
2010 “Farmacopoeia Brasileira, Vol. 2, Monografias 5a edição”) com-
prises only 55 herbal drug aggregates (see Table 3). The 359 herbal
medicinal products licensed in Brazil contain herbal drugs derived from
101 different species (Carvalho et al., 2018). Of these “eight are native
endemic, 19 are native non-endemic, six are naturalized, six are culti-
vated, and 62 are not originated in Brazil” (Carvalho et al., 2018). Since
those cultivated and naturalized species are all exotic to Brazil of the
101 species, only 27 are native (27%). Thus herbal drug species of
products registered with ANVISA and those included in the Brazilian
Pharmacopoeia are for the larger part exotic to Brazil (Table 3; Figs. 2
and 3). This was partially explained with the better documentations of
efficacy and safety, as well as existing quality standard requirements
and control protocols for non-native herbal drugs (Carvalho et al.,
2018).
Thus, currently, and in spite of the higher biodiversity of Brazil with
respect to Europe, the Brazilian Pharmacopoeia includes a considerably
lower share of native species (ca. 27%) when compared to the European
Pharmacopoeia (44%) (Figs. 1 and 2, Tables 1–3) and the number of
licenced herbal medicines is relatively small when compared inter-
nationally (Carvalho et al., 2018).
Currently, among the 20 best-selling herbal medicines in Brazil,
only one product derives from a species (Cordia curassavica (Jacq.)
Roem. & Schult., syn. Cordia verbenacea A.DC.) native to Brazil (Dutra
et al., 2016) and among the 12 herbal medicines available through the
public health care system in Brazil, 8 were developed from exotic plant
species. These data are a reflection of the Brazilian herbal and
Table 2
Number of monographs including herbal drug species in each edition of the
official Brazilian Pharmacopoeia.
aAdopted from Brandão et al. (2006) and ANVISA (2010).
Edition Number (%) of monographs
Native Others Total
1st edition (1929) 196 (27.5) 517 (72.5) 713
2st edition (1959) 32 (15.6) 173 (84.4) 205
3st edition (1977) 4 (17.4) 19 (82.6) 23
4st edition (1996) 11 (25) 33 (75) 44
5st edition (2010) 15 (26.9) 41 (73.1) 56
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phytotherapeutic policies (BRASIL, 2006a, 2006b), notwithstanding
that these claim “… it prioritizes the biodiversity of the country [Brazil]
…”. Of the five main lists of medicinal plant species2 formulated by
Brazilian government agencies aiming at encouraging the utilization,
study and development of herbal medicines around 65% are exotic
(supplementary Table C). In line with these official documents, the 263
research groups working with medicinal plants (CNPq, 2018) and the
pharmaceutical laboratories of Brazil developing herbal medicines pay
little attention to native species of Brazil.
With the new patent law adopted in Brazil in 1996, an increase in
the number of herbal medicines deriving from the Brazilian flora was
expected but the registration process was afflicted with inefficiency and
bureaucratic issues (Hasenclever et al., 2017). With the legalization of
generic drugs in Brazil in 1999 the pharmaceutical industry con-
centrated their investments in the production and commercialization of
generic drugs (Pontes, 2017). That only few native species are used for
the production of herbal medicinal products in Brazil might also be
associated with the restrictive framework regulating access to biodi-
versity from 2001 (Carvalho et al., 2018). The new law (n° 13,123, May
2015) regulates research with biodiversity in Brazil as well as the access
and protections of associated traditional knowledge in a more
transparent way specifying benefit-sharing mechanisms. Moreover, in a
process aligning the Brazilian legislation with international standards,
next to “herbal medicines”, for which clinical and non-clinical trials are
mandatory for registration, now also “traditional herbal products” are
distinguished, for which the documented traditional use (at least 30
years) is regarded as a proxy for safety and effectiveness (Carvalho
et al., 2018). This simplification for licencing herbal medicinal products
is expected to lead to new registrations making use of local traditional
herbal practices.
For example, of the 335 plant species presented in the book ‘Plantas
Medicinais no Brasil’ by Lorenzi and Matos (2008) 135 are exotic and
200 (60%) are native. In total 177 native species, which are referenced
by Lorenzi and Matos (2008) and used in traditional and folk medicine
in Brazil, are neither part of licenced products nor included in the
Brazilian Pharmacopoeia (Fig. 3). Only 12 herbal drug species (4 of
them native) are simultaneously contained in the Brazilian Pharmaco-
poeia, present among the herbal medicinal products licensed and in-
cluded in the book by Lorenzi and Matos (2008; Fig. 3, Table 3). As
many ethnopharmacological field studies have shown, the herbal
knowledge of people and communities in Brazil exceeds by far the
herbal knowledge described in Lorenzi and Matos (2008).
8. Conclusions
Notwithstanding the higher biodiversity of Brazil with respect to
Europe, the Brazilian Pharmacopoeia includes a considerably lower
share of native herbal drugs when compared to the European
Pharmacopoeia. We associate this discrepancy to several factors linked
with biogeographic preconditions, disparate historical developments of
medicine and pharmacy as well as cultural evolution at large.
Accumulated evidence suggests that at the time of the Conquest the
epidemiology of the Amerindian populations resembled more that of
Fig. 2. Map showing the natural geographical distribution of the herbal species mentioned in the 5th edition of the Brazilian Pharmacopoeia (2010). The pie chart
starts at 12:00 (Africa 5%).
2 1. Renisus (DAF, 2009), Anexo da RDC 10/2010 (revogada) [Annex of the
RDC 10/2010 (retracted)] 2. Formulário de Fitoterápicos da Farmacopeia
Brasileira (ANVISA, 2011) [Schedule of phytotherapeutics of the Brazilian
Pharmacopoeia (ANVISA, 2011)] 3. Relação Nacional de Medicamentos Es-
senciais (RENAME, 2015) [National Relation of Essential Medicines (RENAME/
2015)] 4. Memento Fitoterápico da Farmacopeia Brasileira (ANVISA, 2016)
[Phytotherapeutic notes of the Brazilian Pharmacopoeia] and 5. Formulário de
Fitoterápicos da Farmacopeia Brasileira – Primeiro Suplemento (ANVISA, 2018)
[Schedule of phytotherapeutics of the Brazilian Pharmacopoeia, First Supple-
ment].
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pre-agriculturalist societies, while no written consensus around effica-
cious medicine existed. The trial and error approach using biodiversity
for the treatment of infections and symptoms associated with crowd
diseases seems to have begun in the Americas only after the Conquest.
Consequently, the time local medicines in the New World were em-
pirically tested for the treatment of these frequent afflictions was
inferior when compared to Eurasia and Africa. The East-West orienta-
tion of Eurasia facilitated the successful exchange of germplasm of well-
tried plant species over wide areas and the building of a consensus
around efficacious medicine. On the other hand did the high species
richness in the Neotropics together with the lack of written languages
aggravate the exchange and conservation of knowledge. After the
Table 3
Herbal species mentioned in the 5th edition of the Brazilian Pharmacopoeia (2010), herbal species present in products registered with ANVISA (A) and herbal species
popularly used as medicine in Brazil according to Lorenzi and Matos (2008; L).
Herbal taxon Family Drug Portuguese/popular N/E A L
Aesculus hippocastanum L. Hippocastanaceae Hippocastani semen Castanha-da-Índia E x
Anethum graveolens L. Apiaceae Anethi fructus Endro E
Arachis hypogaea L. Fabaceae Arachidis oleum Óleo-de-amendoim E
Arnica montana L. Asteraceae Arnicae flos Arnica E x
Atropa belladonna L. Solanaceae Belladonnae folium Beladona E x
Baccharis trimera (Less.) DC. (Syn. Baccharis crispa Spreng.) Asteraceae Baccharis trimerae herbae Carqueja, carqueja-amarga N x
Calendula officinalis L. Asteraceae Calendulae flos Calêndula E x x
Centella asiatica (L.) Urban Apiaceae Centellae folium Centela E x x
Cinchona calisaya Weddell Rubiaceae Cinchonae cortex Quina-amarela E x x
Cinnamomum cassia (L.) J. Presl Lauraceae Cinnamomi cortex Canela-da-China E
Cinnamomum verum J. Presl Lauraceae Cinnamomi cortex Canela-do-Ceilão E x x
Citrus aurantium L. subsp. aurantium Rutaceae Aurantii amari exocarpium Laranja-amarga E x
Cola nitida (Vent.) A.Chev Sterculiaceae Colae semen Noz-de-cola E
Crataegus spp. Rosaceae Crataegi folium cum flore Cratego E x
Curcuma longa L. Zingiberaceae Curcumae longae rhizome Cúrcuma E x x
Cymbopogon citratus (DC.) Stapf Poaceae Cymbopogonis foliae Capim-limão, Capim-cidró,
Capim-santo
E x
Datura stramonium L. Solanaceae Stramonii folium Estramônio E x
Echinodorus grandiflorus (Cham. & Schltdl.) Micheli Alismataceae Echinodorus folium Chapéu-de-couro N x
Elettaria cardamomum (L.) Maton Zingiberaceae Cardamomi semen Cardamomo E
Eugenia uniflora L. Myrtaceae Eugeniae folium Pitangueira N x
Gentiana lutea L. Gentianaceae Gentianae rhizoma et radix Genciana E x
Hamamelis virginiana L. Hamamelidaceae Hamamelidis tinctura Tintura de hamamélis E x
Hydrastis canadensis L. Ranunculaceae Hydrastidis radix Hidraste E
Hyoscyamus niger L. Solanaceae Hyoscyami folium Meimendro E
Illicium verum Hook. f. Magnoliaceae Anisi stellati fructus Anis-estrelado, badiana,
badiana-da-China
E
Krameria triandra Ruiz & Pav. Krameriaceae Ratanhiae radix Ratânia E
Maytenus ilicifolia Mart. ex Reissek (Syn. Monteverdia
ilicifolia (Mart. ex Reissek) Biral)
Celastraceae Mayteni folium Espinheira-santa N x x
Melissa officinalis L. Lamiaceae Melissae folium Melissa E x x
Mentha x piperita L. Lamiaceae Menthae piperitae folium, Menthae
piperitae aetheroleum
Hortelã-pimenta,
Óleo essencial de hortelã-
pimenta
E x
Myroxylon balsamum (L.) Harms and Myroxylon balsamum
var. pereirae (Royale) Harms
Fabaceae Balsamum tolutanum Bálsamo-de-tolu N x x
Myroxylon balsamum (L.) Harms var. pereirae (Royle)
Harms
Fabaceae Balsamum peruvianum Bálsamo-de-Peru E
Olea europaea L. Oleaceae Olivae oleum virginum Azeite de oliva E
Passiflora alata Curtis Passifloraceae Passiflorae dulcis folium Maracujá-doce N x
Passiflora edulis Sims Passifloraceae Passiflorae acetum folium Maracujá-azedo N x x
Paullinia cupana Kunth Sapindaceae Paulliniae semen Guaraná N x x
Persea americana Mill. Lauraceae Persea folium Abacateiro E x x
Peumus boldus Molina Monimiaceae Boldus folium Boldo E x
Phyllanthus niruri L. Phyllanthaceae Phyllanthus niruri herbae Quebra-piedra N x
Phyllanthus tenellus Roxb Phyllanthaceae Phyllanthus tenellus herbae Quebra-piedra N
Pilocarpus microphyllus Stapf Rutaceae Jaborandi tinctura Tintura de jaborandi N x
Pimpinella anisum L. Apiaceae Anisi fructus Anis-doce, Erva-doce E x
Polygala senega L. Polygalaceae Senegae radix Polígala x
Quillaja saponaria Molina Quillajaceae Quillaiae cortex Quilaia E
Rauvolfia serpentina (L.) Benth. ex Kurz Apocynaceae Rauvolfi ae radix Rauvolfia E
Rheum palmatum L. and/or Rheum officinale Baill. Polygonaceae Rhei rhizoma et radix Ruibarbo E x
Rosmarinus officinalis L. Lamiaceae Oleum rosmarini aetheroleum Óleo essencial de alecrim E x
Salix alba L. Salicaceae Salicis cortex Salgueiro-branco E x
Sambucus australis Cham. & Schltdl Caprifoliaceae [Adoxaceae] Sambucus australis flos Sabugueiro-do-Brazil N x
Sambucus nigra L. Caprifoliaceae [Adoxaceae] Sambucus nigra flos Sabugueiro E
Senna alexandrina Mill. Fabaceae Sennae folium Sene E x
Sesamum indicum L. Pedaliaceae Sesami oleum Óleo-de-gergelim E x
Stevia rebaudiana (Bertoni) Bertoni Asteraceae Steviae folium Estévia N x
Stryphnodendron adstringens (Mart.) Coville Fabaceae Barbadetimani cortex Barbatimão N x x
Styrax benzoin Dryander or Styrax paralleloneuron
Perkins
Styracaceae Benzoe sumatranus Benjoim E
Vanilla planifolia Andrews Orchidaceae Vanillae fructus Baunilha N
N: Native to Brazil; E: Exotic to Brazil; A: ANVISA (Carvalho et al., 2018); L: Lorenzi and Matos (2008).
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colonization of the New World introduced and proven plant species
empirically tested over millennia in the Old World gained therapeutic
importance in the New World. Meanwhile the longstanding and cu-
mulative pharmacognostic research activities in Europe and the USA
focusing on the herbal drugs important in their pharmacopoeias re-
sulted in an accumulation of herbal drugs with the status as safe and
efficacious persisting in pharmacopoeias. The ethnopharmacological
field studies conducted in the Neotropics are useful for highlighting
consensus around the use of herbal medicines but seem to not have
been able to include much data from Amerindian communities living in
the Amazon in the past decades. This results often in studies lacking
novelty reporting common herbal drug species, whether native or in-
troduced. After the boom of the pharmaceutical industry resulting from
the legalization of generic drugs, herbal medicinal products deriving
from local biodiversity could represent timely and innovative products
for investing the generated profits. Newly adopted regulations re-
garding access to biodiversity and traditional knowledge as well as the
simplified procedure for licencing herbal medicinal products in Brazil
prospects an interesting future for ethnopharmacologists and those
aiming at developing herbal medicine based on bio-cultural diversity.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.jep.2019.111891.
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